abs

학술발표회초록보기

초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 09월 04일 13시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

The face of future hepatitis C antiviral drug development

등록일
2009년 8월 27일 17시 21분 16초
접수번호
1598
발표코드
목18F6심 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
발표시간
목 16시 : 20분
발표형식
심포지엄
발표분야
의약화학 - Current Struggles against Infectious Diseases
저자 및
공동저자
장승기
포항공과대학교 생명과학과, Korea

Chronic hepatitis C virus (HCV) infection is a worldwide health problem. More than 170 million people are estimated to be infected by HCV, and HCV infections results in hepatitis, liver cirrhosis, and hepatocellular carcinoma. Response rates to current standard of treatment (pegylated IFNs and ribavirin) are low in patients with the prevailing genotype 1. Therefore, development of new drugs for HCV infection is urgently needed. Potential therapeutic targets for new drugs, current status of anti-HCV drug development, and new approaches to develop new anti-HCV drugs will be discussed. Moreover, our efforts to find a cellular protein (GRP94) required for HCV proliferation and the effects of chemicals inhibiting GRP94 in HCV proliferation will be discussed. Moreover, the effects of aptamers against HCV E2 on viral infection will be presented.


상단으로